Viewpoint News & Awards

Viewpoint Awarded $300,000 NCI Phase I SBIR

October 7, 2015 (Coralville, IA) – Viewpoint is pleased to announce it has secured a third consecutive collaborative Small Business Innovation Research (SBIR) Grant ($300,000), awarded by the National Institutes of Health. Viewpoint will focus on the development of its novel image-guided therapy for metastatic melanoma. “Viewpoint is excited about the momentum of its lead compound” states Frances Johnson MD, Chief Medical Officer of Viewpoint. “This award fuels our efforts in our initiatives”.

This contract with NIH is an exciting milestone for our company to bring our therapy platform one big step further toward metastatic melanoma patient care,” says Michael Schultz, PhD, CSO of Viewpoint (also Associate Professor in the Departments of Radiology, Radiation Oncology, and Chemistry at University of Iowa). “Our network of collaborators is paving the way toward clinical trials and commercialization of our new platform technologies.”

Viewpoint’s products are currently under development and therefore not approved by the FDA.